QIM26-313: Improving Molecular Testing Rates in Advanced Thyroid Cancer Through a Standardized Testing Pathway
Lauren Shih(University of Washington), Christina Rodriguez(University of Washington), Vera Paulson(University of Washington), Mara Y. Roth(University of Washington), Christina S. Baik(Seattle Cancer Care Alliance), Keith D. Eaton(Seattle Cancer Care Alliance), Nicholas Giustini(University of Washington), Lei Deng(University of Washington), S. Menon(University of Washington), Rafael Santana Davila, Sylvia Lee(University of Washington), Diane Tseng(Stanford University), Erik Konnick(University of Washington), Perrin E. Romine
Cited by 0
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|514
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
|Cell|2020|360